Halozyme Therapeutics, Inc.
HALO
$74.93
$1.532.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 22.98% | -11.12% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 22.98% | -11.12% | |||
| Cost of Revenue | -10.21% | -17.38% | |||
| Gross Profit | 31.01% | -9.46% | |||
| SG&A Expenses | -1.77% | 0.27% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.04% | 0.67% | |||
| Operating Income | 43.03% | -19.35% | |||
| Income Before Tax | 42.49% | -19.29% | |||
| Income Tax Expenses | 54.58% | -37.54% | |||
| Earnings from Continuing Operations | 39.85% | -13.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 39.85% | -13.81% | |||
| EBIT | 43.03% | -19.35% | |||
| EBITDA | 37.98% | -17.50% | |||
| EPS Basic | 42.02% | -11.58% | |||
| Normalized Basic EPS | 46.43% | -17.07% | |||
| EPS Diluted | 43.01% | -12.41% | |||
| Normalized Diluted EPS | 47.08% | -17.68% | |||
| Average Basic Shares Outstanding | -1.52% | -2.52% | |||
| Average Diluted Shares Outstanding | -1.96% | -1.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||